Table 2 Rate ratios (RR) of diabetes-related complications according to lipid lowering drug use (A) and antihypertensive drug use (B)

Cardiovascular disease

(0.73–0.98)

(0.49–0.71)

(1.21–1.73)

Cerebrovascular disease

(0.74–1.12)

(0.45–0.76)

(1.21–2.03)

Ischeamic heart disease

(0.96–1.42)

(0.56–0.92)

(1.27–2.1)

Heart failure

(0.8–1.33)

(0.51–0.98)

(1.04–2.07)

Atherosclerotic macrovascular disease

(0.8–1.34)

(0.49–0.95)

(1.08–2.12)

Atrial fibrillation

(0.67–1.13)

(0.44–0.86)

(1.01–1.99)

Chronic Kidney disease

(0.7–1.14)

(0.51–0.95)

(0.93–1.78)

Severe chronic kidney disease

(0.52–2.9)

(0.29–1.79)

(0.62–4.6)

End-stage chronic kidney disease

(0.58–1.15)

(0.33–0.73)

(1.11–2.48)

Microalbuminuria

(0.9–1.2)

(0.64–0.91)

(1.14–1.62)

Macroalbuminuria

(0.71–1.3)

(0.51–1.06)

(0.91–1.89)

Minor amputation

(0.46–1.09)

(0.39–1.2)

(0.59–1.83)

Major amputation

(0.65–1.57)

(0.31–0.85)

(1.16–3.35)

Moderate-severe retinopathy

(0.83–1.24)

(0.63–1.05)

(0.97–1.6)

Cardiovascular Disease

(2.46–3.86)

(0.75–1.27)

(2.43–4.09)

Cerebrovascular disease

(1.89–3.67)

(0.5–1.03)

(2.54–5.29)

Ischeamic heart disease

(1.94–3.69)

(0.9–1.86)

(1.4–3.05)

Heart failure

(5.47–13.81)

(0.76–1.77)

(4.39–12.69)

Atherosclerotic macrovascular disease

(1.85–4.48)

(0.9–2.43)

(1.1–3.43)

Atrial fibrillation

(1.88–4.42)

(0.84–2.38)

(1.14–3.62)

Chronic Kidney disease

(9.6–23.67)

(2.23–6.4)

(2.15–7.4)

Severe chronic kidney disease

(13.99–1191.92)

(1.07–16.55)

(2.73–344.77)

End-stage chronic kidney disease

(13.63–40.5)

(2.08–7.08)

(2.97–12.66)

Microalbuminuria

(1.4–2.54)

(0.81–1.45)

(1.28–2.38)

Macroalbuminuria

(7.05–25.8)

(1.01–3.01)

(3.86–15.51)

Minor amputation

(1.56–7.24)

(0.86–4.47)

(0.66–4.41)

Major amputation

(1.74–6.75)

(1.16–7.13)

(0.43–3.28)

Moderate-severe retinopathy

(0.69–1.63)

(0.4–0.95)

(1.13–2.57)